Skip to main
RCEL
RCEL logo

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical demonstrated significant financial growth in its fourth quarter, with commercial revenue reaching $18.4 million, marking a 30% year-over-year increase, indicative of its successful market penetration of the RECELL system. The company enjoys a healthy gross profit margin of 87.6%, underscoring its pricing power and operational efficiency, while recent FDA approvals for additional products enhance its treatment capabilities and potential market share in acute wound care. With strategic investments in sales and commercialization, along with forthcoming product launches and regulatory advancements set for 2025, AVITA Medical is poised for accelerated revenue growth in the near future.

Bears say

Avita Medical's narrow focus on a single product, the RECELL system, limits its market potential and revenue diversification, which raises concerns about long-term sustainability. The company's strategy to prioritize the US market over available international opportunities may hinder growth, particularly as it faces increased competition in the burn treatment sector. Additionally, despite product approval in multiple regions, the lack of active marketing outside the US suggests potential underutilization of its global footprint, contributing to a cautious financial outlook.

RCEL has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 6 analysts, RCEL has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.